Between the Lines is an engaging 30- to 45-minute open discussion showcasing insightful and impactful perspectives from oncologists and advanced practice providers on published, peer-reviewed content.
Tivozanib Plus Nivolumab vs Tivozanib Monotherapy in RCC Following an Immune Checkpoint Inhibitor The Phase 3 TiNivo-2 Study
Between the Lines: Recent Updates in Treatment and Strategies for Managing Adverse Events in Multiple Myeloma
Relacorilant/Nab-Paclitaxel Is Convenient, Safe in Ovarian Cancer
Neoadjuvant Nivolumab Regimen Improves OS in Resectable NSCLC
Relacorilant Combo Boosts PFS in Resistant Ovarian Cancer
Nivolumab/Ipilimumab To Be New MSI-H/dMMR mCRC Standard of Care